What K2 and kratom reveal about today’s changing drug supply
Kratom Use, Synthetic Cannabinoids (K2), and Trends in the Drug Supply.
AI Summary
Kratom and synthetic cannabinoids—often sold as K2—are psychoactive substances whose popularity has grown alongside limited regulation. Kratom contains mitragynine and 7-hydroxymitragynine, compounds that can produce both opioid-like and stimulant effects. The abstract warns that users may face opioid toxicity, withdrawal, and contamination-related harms.
Although synthetic cannabinoids act on cannabinoid receptors, they are chemically different from cannabis. Their reported harms include psychosis, seizures, stroke, and heart attack, as well as dependence-related behaviors. A central challenge is that attempts to regulate these products can be quickly overtaken by new compounds designed to evade existing rules. The abstract does not report quantitative results, but its practical message is clear: products marketed as legal or cannabis-like may carry serious and unpredictable risks.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Mental Health research papers you might find interesting.
Brain blood-flow reductions in acute anorexia follow a cortical hierarchy
CBD showed limited adaptive-functioning differences versus placebo in boys…
Resilience linked to depression outcomes and THC positivity
Explore More Research
Stay informed about the latest cannabis science.